annual EBIT:
-$463.22M-$131.19M(-39.51%)Summary
- As of today (September 18, 2025), RXRX annual earnings before interest & taxes is -$463.22 million, with the most recent change of -$131.19 million (-39.51%) on December 31, 2024.
- During the last 3 years, RXRX annual EBIT has fallen by -$279.69 million (-152.40%).
- RXRX annual EBIT is now -656.35% below its all-time high of -$61.24 million, reached on December 31, 2019.
Performance
RXRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$171.42M+$30.72M(+15.20%)Summary
- As of today (September 18, 2025), RXRX quarterly earnings before interest & taxes is -$171.42 million, with the most recent change of +$30.72 million (+15.20%) on June 30, 2025.
- Over the past year, RXRX quarterly EBIT has dropped by -$73.75 million (-75.51%).
- RXRX quarterly EBIT is now -845.85% below its all-time high of -$18.12 million, reached on March 31, 2020.
Performance
RXRX quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$646.97M-$73.75M(-12.87%)Summary
- As of today (September 18, 2025), RXRX TTM earnings before interest & taxes is -$646.97 million, with the most recent change of -$73.75 million (-12.87%) on June 30, 2025.
- Over the past year, RXRX TTM EBIT has dropped by -$267.14 million (-70.33%).
- RXRX TTM EBIT is now -3469.88% below its all-time high of -$18.12 million, reached on March 31, 2020.
Performance
RXRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RXRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -39.5% | -75.5% | -70.3% |
| 3 y3 years | -152.4% | -161.5% | -176.9% |
| 5 y5 years | -656.4% | -825.7% | -1665.8% |
RXRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -152.4% | at low | -198.2% | +15.2% | -176.9% | at low |
| 5 y | 5-year | -656.4% | at low | -825.7% | +15.2% | -1665.8% | at low |
| alltime | all time | -656.4% | at low | -845.9% | +15.2% | -3469.9% | at low |
RXRX EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$171.42M(-15.2%) | -$646.97M(+12.9%) |
| Mar 2025 | - | -$202.14M(+13.4%) | -$573.22M(+23.7%) |
| Dec 2024 | -$463.22M(+39.5%) | -$178.29M(+87.4%) | -$463.22M(+21.3%) |
| Sep 2024 | - | -$95.12M(-2.6%) | -$381.95M(+0.6%) |
| Jun 2024 | - | -$97.67M(+6.0%) | -$379.82M(+5.8%) |
| Mar 2024 | - | -$92.13M(-5.0%) | -$358.86M(+8.1%) |
| Dec 2023 | -$332.03M(+38.7%) | -$97.03M(+4.3%) | -$332.03M(+13.5%) |
| Sep 2023 | - | -$92.99M(+21.2%) | -$292.48M(+12.5%) |
| Jun 2023 | - | -$76.70M(+17.4%) | -$259.92M(+4.5%) |
| Mar 2023 | - | -$65.31M(+13.6%) | -$248.76M(+3.9%) |
| Dec 2022 | -$239.42M | -$57.48M(-4.9%) | -$239.42M(-3.0%) |
| Sep 2022 | - | -$60.43M(-7.8%) | -$246.90M(+5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$65.55M(+17.1%) | -$233.67M(+11.8%) |
| Mar 2022 | - | -$55.97M(-13.8%) | -$209.03M(+13.9%) |
| Dec 2021 | -$183.53M(+114.3%) | -$64.95M(+37.6%) | -$183.53M(+27.4%) |
| Sep 2021 | - | -$47.21M(+15.4%) | -$144.11M(+19.7%) |
| Jun 2021 | - | -$40.90M(+34.2%) | -$120.38M(+22.8%) |
| Mar 2021 | - | -$30.47M(+19.3%) | -$97.99M(+14.4%) |
| Dec 2020 | -$85.65M(+39.8%) | - | - |
| Dec 2020 | - | -$25.54M(+8.8%) | -$85.65M(+42.5%) |
| Sep 2020 | - | -$23.47M(+26.8%) | -$60.11M(+64.1%) |
| Jun 2020 | - | -$18.52M(+2.2%) | -$36.64M(+102.2%) |
| Mar 2020 | - | -$18.12M | -$18.12M |
| Dec 2019 | -$61.24M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual earnings before interest & taxes?
- What is the all time high annual EBIT for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual EBIT year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM EBIT year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual earnings before interest & taxes?
The current annual EBIT of RXRX is -$463.22M
What is the all time high annual EBIT for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$61.24M
What is Recursion Pharmaceuticals, Inc. annual EBIT year-on-year change?
Over the past year, RXRX annual earnings before interest & taxes has changed by -$131.19M (-39.51%)
What is Recursion Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of RXRX is -$171.42M
What is the all time high quarterly EBIT for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is -$18.12M
What is Recursion Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
Over the past year, RXRX quarterly earnings before interest & taxes has changed by -$73.75M (-75.51%)
What is Recursion Pharmaceuticals, Inc. TTM earnings before interest & taxes?
The current TTM EBIT of RXRX is -$646.97M
What is the all time high TTM EBIT for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is -$18.12M
What is Recursion Pharmaceuticals, Inc. TTM EBIT year-on-year change?
Over the past year, RXRX TTM earnings before interest & taxes has changed by -$267.14M (-70.33%)